• PI3Kδ inhibitor leniolisib improves symptoms in patients with APDS/PASLI

    Leniolisib is safe, increases naïve B cells, decreases lymphadenopathy and spleen size, and improves cytopenia in APDS/PASLI.

  • Early ASCT to triplet therapy improves PFS in multiple myeloma

    Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM

  • Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin

    Exa-cel gene-editing therapy is associated with increase in foetal and total Hb in transfusion-dependent β-thalassemia or severe sickle cell disease patients.

  • Triple-therapy improves PFS in fit, previously untreated CLL patients

    Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.

  • Hack Your Care opens the doors to innovation in health

    A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.

  • No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics

    CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.

  • Luspatercept benefits transfusion-dependent β-thalassemia patients after 3 years

    Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden.

  • New subtypes of oncogenic deregulation in childhood T-ALL uncovered

    Large-scale whole-genome sequencing, whole-exome sequencing, and RNA-expression profiling found new T-cell acute lymphoblastic leukaemia subtypes.

  • Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML patients

    OS improves when combined with standard induction and consolidation therapy, and as continuation therapy as a single agent for up to 3 years in patients.

  • Axi-cel: Superior in older relapsed / refractory large-B-cell lymphoma patients

    A subgroups analysis of patients aged 65 years or older in ZUMA-7 demonstrated axi-cel to be superior to standard-of-care for second-line treatment.

  • Caplacizumab is safe and effective in patients with iTTP

    Post-trial data support caplacizumab's long-term safety and efficacy in acquired or immune-mediated thrombotic thrombocytopenic purpura patients.

  • Abscopal response observed in HL patients who failed on anti-PD treatment

    Nivolumab and radiotherapy at a single lesion is well tolerated and leads to an abscopal response in most of relapsed/refractory HL cases.

  • Momelotinib: rapid and sustained improvement in Hbg for myelofibrosis patients

    The phase 3 MOMENTUM trial show a significant improvement in symptoms, spleen size, and anaemia measures with momelotinib over danazol.

  • Carfilzomib, lenalidomide, and dexamethasone outperforms lenalidomide in MM

    Phase-3 ATLAS trial shows the post-transplant maintenance therapy benefit of carfilzomib, lenalidomide, and dexamethasone over lenalidomide.

  • Pan-clonal score predicts first-line treatment response in AML

    AML has high patient-to-patient treatment response variability. Pharmacoscopy allows ex vivo drug-response profiling of tumour cells, enabling tailored treatments.

  • How DNA diagnostics began: The Colin Pitchfork murder case

    In 1983 and 1986, the British police struggle with two murders. Until geneticist Dr. Alec Jeffreys brought us RFLP. Genetic fingerprinting was born.

  • Case Report: Unexpected Tumour Reduction after PARP Inhibition

    After third-line failure, a 61-year-old female patient with metastatic pancreatic ductal adenocarcinoma received off-label monotherapy with olaparib.

  • New figures show the pandemic’s impact on health professionals

    OVer two years into the pandemic, a global emergency medicine professionals survey reveals that 62% reported one or more COVID-19-related burnout symptoms.

  • The eye as a privileged organ: aspects of corneal transplantation

    The human eye has immunological peculiarities. The graft rejection rate, for example, is just 10%. For non-vascularised corneas only about 2%.

  • Screening Factor for Pancreatic Ductal Adenocarcinoma Discovered

    A Spanish-German team of scientists may have made a breakthrough in the search for a reliable screening method for pancreatic cancer.

  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |